Publications

5891 Results

Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy?

Authors
EA Perez;VJ Suman;NE Davidson;PA Kaufman;S Martino;SR Dakhil;JN Ingle;RJ Rodeheffer;BJ Gersh;AS Jaffe
Journal / Conference
Breast Cancer Research and Treatment 94(Suppl 1):S96(#2038)
Year
2005
Research Committee(s)
Breast
Study Number(s)
N9831

HIGH expression of the microtubule-associated protein, tau, strongly predicts improved progression free and overall survival in patients with metastatic HER-2 negative breast cancers treated with docetaxel and vinorelbine plus filgrastim

Authors
AM Gown;DO Treaba;LC Goldstein;PL Porter;JR Gralow;RB Livingston;S Tam;IT Yeh;DF Hayes;W Barlow;D Lew
Journal / Conference
Breast Cancer Research and Treatment 94(Suppl 1):S50(#1035)
Year
2005
Research Committee(s)
Breast
Study Number(s)
S0102

Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective.

Authors
C Hudis;M Citron;D Berry;C Cirrincione;W Gradishar;N Davidson;S Martino;R Livingston;J Ingle;E Perez;J Abrams;R Schilsky;M Ellis;H Muss;L Norton;E Winer
Journal / Conference
Breast Cancer Research and Treatment 94(Suppl 1):S20-S21(#41)
Year
2005
Research Committee(s)
Breast
Study Number(s)
C9741

A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). a Southwest Oncology Group (SWOG) trial

Authors
S Williamson;J Moon;C Huang;G Wolf;S Urba
Journal / Conference
European Journal of Cancer Supplements 3(2):286 (#995)
Year
2005
Research Committee(s)
Head and Neck
Study Number(s)
S0420

Ixabepilone (epothilone b analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111

Authors
M Hussain;CM Tangen;PN Lara;UN Vaishampayan;DP Petrylak;AD Colevas;WA Sakr;ED Crawford
Journal / Conference
Journal of Clinical Oncology 23(34):8724-8729
Year
2005
Research Committee(s)
Genitourinary
Study Number(s)
S0111

Meta-analysis to evaluate the role of interferon in follicular lymphoma.

Authors
AZS Rohatiner;WM Gregory;B Peterson;E Borden;P Solal-Celigny;A Hagenbeek;RI Fisher;M Unterhalt;R Arranz;T Chisesi;A Aviles;TA Lister
Journal / Conference
Journal of Clinical Oncology 23(10):2215-2223
Year
2005
Research Committee(s)
Lymphoma

Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.

Authors
EA Klein;CM Tangen;PJ Goodman;SM Lippman;IM Thompson
Journal / Conference
Journal of Clinical Oncology 23(30):7460-7466
Year
2005
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Erectile dysfunction and subsequent cardiovascular disease

Authors
IM Thompson;CM Tangen;P Goodman;JL Probstfield;CM Moinpour;CA Coltman
Journal / Conference
JAMA 294(23):2996-3002
Year
2005
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG 8794)

Authors
G Swanson;I Thompson;C Tangen;G Miller;MS Lucia;D Troyer;J Paradelo;J Chin;E Messing;E Canby-Hagino;J Forman;ED Crawford
Journal / Conference
Proc ASTRO, Int J Radiat Oncol Biol Phy 63 (Suppl 1):S1 (#1), 2005.
Year
2005
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8794

Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies

Authors
RI Fisher
Journal / Conference
Journal of Clinical Oncology 23(4):657-658
Year
2005
Research Committee(s)
Lymphoma